A recent trial has shown a notable increase in atrial arrhythmias, occurring in nearly one in four patients within the first month following PFO closure when monitored with intracardiac devices. This incidence is significantly higher than previously reported rates of symptomatic arrhythmias, which ranged from 3-5%.
Flecainide, a common anti-arrhythmic, did not reduce the frequency of these arrhythmias, raising important questions about effective management approaches. These findings highlight the need for careful monitoring, especially in older patients who may have pre-existing conditions, as well as a reconsideration of current protocols for post-PFO closure care.
Source: www.acc.org/Latest-in-Cardiology/Clinical-Trials/2024/11/11/15/53/afloat
